Alternating teclistamab and pomalidomide for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs, teclistamab and pomalidomide, given in an alternating schedule, for people with multiple myeloma that has relapsed or become resistant to standard treatments. The goal is to see if this combination helps control the cancer and is safe to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of multiple myeloma that has come back or has not responded to prior treatment.
- You must have received 1 to 3 prior lines of therapy, including at least 2 cycles of a CD38-targeting drug (like daratumumab) and at least 2 cycles of lenalidomide (Revlimid).
- You cannot have been treated with any therapy that targets BCMA (a protein on myeloma cells) before.
- You need to be generally well enough to perform daily activities (ECOG score 0–2) and have adequate organ function.
- You must be willing to follow strict contraception rules if needed (no egg or sperm donation during and after the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
This study tests a new combination for multiple myeloma that has come back or not responded to earlier treatments. It uses a drug called teclistamab (which helps your immune system attack myeloma cells) along with an infusion of your own immune cells (lymphocytes) to potentially improve the response.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
This trial tests a new combination of two medicines (etentamig and pomalidomide) against standard treatments for people whose multiple myeloma has returned or not responded to therapy. The goal is to see if this combination works better and is safe.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
Hear when a new Multiple Myeloma Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.